Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Spruce Biosciences, Inc. (SPRB : NSDQ)

• Company Description    Spruce Biosciences Inc. is a biopharmaceutical company. It focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy which are in clinical stage. Spruce Biosciences Inc. is based in Daly City, California. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $57.93 Daily Weekly Monthly 20 Day Moving Average: 75,644 shares Shares Outstanding: 2.87 (millions) Market Capitalization: $166.49 (millions) Beta: 3.31 52 Week High: $240.00 52 Week Low: $7.26 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 25.39% 25.95% 12 Week 16.08% 13.61% Year To Date -33.50% -41.02%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 611 GATEWAY BOULEVARD SUITE 740 - SOUTH SAN FRANCISCO,CA 94080 USA ph: 415-655-4168 fax: - investors@sprucebio.com https://sprucebio.com

• General Corporate Information    Officers Javier Szwarcberg - Chief Executive Officer Michael Grey - Executive Chairman Samir Gharib - President and Chief Financial Officer Camilla V. Simpson - Director Daniel Spiegelman - Director Peer Information Spruce Biosciences, Inc. (CORR.) Spruce Biosciences, Inc. (RSPI) Spruce Biosciences, Inc. (CGXP) Spruce Biosciences, Inc. (BGEN) Spruce Biosciences, Inc. (GTBP) Spruce Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 85209E208 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/09/26 Share - Related Items Shares Outstanding: 2.87 Most Recent Split Date: 8.00 (0.01:1) Beta: 3.31 Market Capitalization: $166.49 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-5.76 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-25.53 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/09/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.90 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -90.86% vs. Previous Quarter: 25.28% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - -123.53 03/31/26 - -155.40 12/31/25 - -203.99 ROA 06/30/26 - -90.35 03/31/26 - -101.67 12/31/25 - -127.96 Current Ratio 06/30/26 - 9.23 03/31/26 - 4.67 12/31/25 - 5.17 Quick Ratio 06/30/26 - 9.23 03/31/26 - 4.67 12/31/25 - 5.17 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - 30.42 03/31/26 - 25.25 12/31/25 - 39.72 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.05 03/31/26 - 0.16 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 5.20 03/31/26 - 13.62 12/31/25 - 0.00

Powered by Zacks Investment Research ©